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Articles
The global burden of childhood and adolescent cancer in 
2017: an analysis of the Global Burden of Disease Study 2017
GBD 2017 Childhood Cancer Collaborators*
Summary
Background Accurate childhood cancer burden data are crucial for resource planning and health policy prioritisation. 
Model-based estimates are necessary because cancer surveillance data are scarce or non-existent in many countries. 
Although global incidence and mortality estimates are available, there are no previous analyses of the global burden 
of childhood cancer represented in disability-adjusted life-years (DALYs).
Methods Using the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 methodology, childhood 
(ages 0–19 years) cancer mortality was estimated by use of vital registration system data, verbal autopsy data, and 
population-based cancer registry incidence data, which were transformed to mortality estimates through modelled 
mortality-to-incidence ratios (MIRs). Childhood cancer incidence was estimated using the mortality estimates and 
corresponding MIRs. Prevalence estimates were calculated by using MIR to model survival and multiplied by 
disability weights to obtain years lived with disability (YLDs). Years of life lost (YLLs) were calculated by multiplying 
age-specific cancer deaths by the difference between the age of death and a reference life expectancy. DALYs were 
calculated as the sum of YLLs and YLDs. Final point estimates are reported with 95% uncertainty intervals.
Findings Globally, in 2017, there were 11·5 million (95% uncertainty interval 10·6–12·3) DALYs due to childhood 
cancer, 97·3% (97·3–97·3) of which were attributable to YLLs and 2·7% (2·7–2·7) of which were attributable to 
YLDs. Childhood cancer was the sixth leading cause of total cancer burden globally and the ninth leading cause of 
childhood disease burden globally. 82·2% (82·1–82·2) of global childhood cancer DALYs occurred in low, low-middle, 
or middle Socio-demographic Index locations, whereas 50·3% (50·3–50·3) of adult cancer DALYs occurred in these 
same locations. Cancers that are uncategorised in the current GBD framework comprised 26·5% (26·5–26·5) of 
global childhood cancer DALYs.
Interpretation The GBD 2017 results call attention to the substantial burden of childhood cancer globally, which 
disproportionately affects populations in resource-limited settings. The use of DALY-based estimates is crucial in 
demonstrating that childhood cancer burden represents an important global cancer and child health concern.
Funding Bill & Melinda Gates Foundation, American Lebanese Syrian Associated Charities (ALSAC), and St. Baldrick’s 
Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Children with cancer who live in high-income countries 
(HICs) have good outcomes, with approximately 
80% surviving 5 years after their diagnosis.1,2 However, 
more than 90% of children at risk of developing 
childhood cancer each year live in low-income and 
middle-income countries (LMICs).3–5 Considered by 
many as one of the major advances of modern science, 
the improvement in outcomes in children with cancer 
seen in HICs over the past several decades has not 
translated to most LMICs, where existing data suggest 
that far fewer children survive.6 An accurate appraisal of 
childhood cancer incidence and outcomes is non-existent 
in many LMICs, due in part to a lack of the cancer 
registry and vital registration systems necessary to record 
and report these data.5,7 Childhood cancers are often fatal 
without appropriate and timely diagnosis and treatment 
and, by contrast with adult cancers, there are no evidence-
based population screening programmes or lifestyle 
risk-reduction strategies that are effective in improving 
outcomes.8,9 As a result, increasing survival will require 
considerable planning by policy makers to ensure 
adequate resource allocation and health system function. 
Information on the burden of childhood cancer is crucial 
to informing these efforts and thus, model-based 
estimates are necessary to determine cancer burden in 
settings without data until cancer data coverage improves.
The Global Burden of Diseases, Injuries, and Risk 
Factors Study (GBD) 2017 provides estimates for 
359 diseases and injuries, including cancers, and is 
therefore uniquely positioned to fill the gap in health 
planning data as countries work to expand their cancer 
surveillance systems.10 Additionally, standard GBD 
outcomes include estimates of disability-adjusted life-
years (DALYs), a useful composite metric that accounts 
for both the mortality and morbidity of a disease.11 DALYs 
allow for cross-disease and cross-geography comparisons 
that contextualise disease burden. So far, however, no 
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dedicated GBD analysis of childhood cancer burden has 
been done. Previous research describing childhood 
cancer burden internationally has focused on traditional 
metrics of cancer burden, including incidence, mortality, 
and survival.6,7,12 We aimed to report the global burden of 
childhood cancer in 2017 using DALY estimates from 
GBD 2017, an approach that adds a new perspective to 
the assessment of childhood cancer burden than has 
been presented in previous analyses.
Methods
Overview
The GBD study was created to establish comprehensive 
and comparable global health metrics. Estimates of 
incidence, prevalence, mortality, years of life lost (YLLs), 
years lived with disability (YLDs), and DALYs are 
generated for each disease and injury, with each metric 
reported by year, location, age group, and sex.13 Each 
successive GBD iteration supersedes the results of 
previous GBD rounds for the entire newly estimated 
time series. GBD 2017 is compliant with the Guidelines 
for Accurate and Transparent Health Estimates Reporting 
(appendix p 4).14 Data sources used in GBD 2017 are 
available online.
Estimation of cancer burden
The GBD cancer estimation process focuses first on the 
estimation of cancer mortality (see appendix pp 7–8 for 
flow diagrams of the GBD 2017 cancer estimation 
process). Cancer mortality data sources include vital 
registration systems, cancer registration systems, and 
verbal autopsy data (a map of the site-years of childhood 
cancer data available in GBD 2017 is available on 
appendix p 10). Cancer registries are active in some 
locations that do not have reliable cancer mortality data, 
and many cancer registries only report incidence. Thus, 
mortality-to-incidence ratios (MIRs) were used to 
transform cancer registry incidence data to mortality 
estimates, maximising data availability in locations with 
scarce mortality information. MIRs for all age, sex, 
location, and year combinations were modelled using a 
spatiotemporal Gaussian process regression with 
incidence data from cancer registries and mortality data 
from cancer registries or high-quality vital registration 
systems. In brief, spatiotemporal Gaussian process 
regression has three steps: logit random effects models, 
spatiotemporal smoothing, and Gaussian process 
regression (appendix p 13; see also the supplementary 
materials for reference 15).15 The mortality estimates 
derived with this approach were pooled with the directly 
obtained mortality data from vital registration systems 
and verbal autopsies, and used in cancer-specific Cause 
of Death Ensemble models (CODEm), which are 
necessary because mortality data do not exist for every 
age, sex, location, and year combination estimated by 
GBD 2017.16 The CODEm approach uses all available 
Research in context
Evidence before this study
Previous work to describe childhood cancer burden globally has 
focused on conventional metrics of cancer burden, such as 
incidence, mortality, and survival, either in a subset of countries 
(eg, the third volume of the International Incidence of Childhood 
Cancer and CONCORD-3) or globally (eg, GLOBOCAN 2018). 
We searched PubMed for English-language research articles 
describing the global burden of childhood cancer published 
between Jan 1, 2010, and Sept 30, 2018, using the terms 
“pediatric or childhood or child” and “cancer or neoplasm or 
tumor or malignancy or oncology” and “global or international 
or worldwide or world” and “burden or metrics or incidence or 
mortality or prevalence or survival” but did not find additional 
applicable work. While providing valuable information, 
no previous publications incorporated morbidity or provided 
disability-adjusted life-years (DALYs), a metric that allows policy 
makers to directly compare the lifelong implications of childhood 
cancer burden against other diseases for priority setting.
Added value of this study
To our knowledge, we report for the first time the global and 
regional estimates of childhood cancer burden using Global 
Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 
results, with DALYs as the outcome measure, providing a new 
perspective on the global burden childhood cancer to that 
previously available in published literature. The global DALY 
burden due to childhood cancers in 2017 is substantial, primarily 
because of fatal burden. This burden is disproportionately high 
in low, low-middle, and middle Socio-demographic Index (SDI) 
settings, which together contribute 82·2% of global childhood 
cancer DALYs. Childhood cancers are a major cause of global 
disease burden, even when compared with other diseases of 
childhood or with adult cancers.
Implications of all the available evidence
By presenting the global burden of childhood cancer in DALYs, 
we identified that childhood cancer results in a substantial 
disease burden despite a relatively low absolute number of 
incident cases and deaths. This burden is particularly notable in 
resource-limited settings, where the ability to directly compare 
the burden of various diseases through DALYs is particularly 
relevant for policy makers, who must consider a myriad of 
health priorities in addition to childhood cancers and can use 
these data to make evidence-based resource allocation and 
cancer-control planning decisions. As countries implement, 
monitor, and evaluate capacity-building programmes as part of 
the WHO Global Initiative for Childhood Cancer, refining the 
methodology of childhood cancer burden estimation in future 
GBD iterations will be crucial to identify high-impact 
interventions and provide the most useful information for 
cancer control efforts by governments, stakeholders, and the 
global health community.
For more on GBD 2017 data 
sources see http://ghdx.
healthdata.org/gbd-2017
Articles
www.thelancet.com/oncology   Vol 20   September 2019 1213
mortality data even if data quality varies, tests individual 
as well as ensemble models, and is capable of selecting 
the optimal model or set of models on the basis of the 
out-of-sample predictive validity. Each CODEm used 
covariates and age group restrictions specific to each 
cancer type (appendix pp 15–34). Cause-specific mortality 
estimates were subsequently scaled to independently 
modelled all-cause mortality.17,18
The mortality estimates for each cancer type were 
divided by the corresponding MIR to obtain incidence 
estimates. 10-year prevalence was modelled using 
estimated survival based on the MIR. Total prevalence 
was divided into sequelae (phases of cancer treatment) to 
estimate the cancer type-specific YLDs (appendix p 34). 
Two sequelae were estimated for cohorts that survive 
10 years after diagnosis: (1) diagnosis or treatment and 
(2) remission, after which disability risk is returned to 
that of the general population. Four sequelae were 
estimated for cohorts that do not survive 10 years after 
diagnosis: (1) diagnosis or treatment, (2) remission, 
(3) metastatic or disseminated, and (4) terminal phases. 
To generate YLD estimates, each sequela prevalence was 
multiplied by a sequelae-specific disability weight, 
representing the magnitude of health loss associated 
with a specific health outcome, measured on a scale from 
0 (full health) to 1 (equivalent to death; appendix p 39).19 
YLLs were estimated by multiplying the difference 
between a standard life expectancy at the age of death 
and the estimated number of deaths at that age.17 The 
YLD and YLL estimates were summed to provide 
Absolute incidence 
(95% UI)
Age-standardised 
incidence rate 
(95% UI)
Absolute mortality 
(95% UI)
Age-standardised 
mortality rate 
(95% UI)
Absolute YLLs 
(95% UI)
Absolute YLDs 
(95% UI)
Absolute DALYs 
(95% UI)
Global 416 500 
(384 900–442 100)
16·2 
(15·0–17·2)
142 300 
(131 500–151 900)
5·5 
(5·1–5·9)
11 236 500 
(10 380 800–12 005 700)
313 100 
(209 600–449 100)
11 549 600 
(10 649 900–12 334 700)
SDI status
High SDI countries 49 700 
(46 200–53 800)
20·8 
(19·3–22·5)
6700 
(6300–7200)
2·7 
(2·6–2·9)
523 100 
(489 100–555 400)
49 700 
(32 200–72 900)
572 800 
(530 700–615 400)
High-middle SDI 
countries
97 600 
(83 100–106 000)
30·1 
(25·5–32·7)
16 900 
(15 300–17 900)
5·1 
(4·6–5·4)
1 326 100 
(1 191 800–1 404 000)
129 900 
(78 400–206 200)
1 456 000 
(1 293 900–1 580 500)
Middle SDI countries 107 300 
(98 500–115 500)
17·1 
(15·7–18·5)
31 900 
(29 800–33 700)
5·0 
(4·6–5·3)
2 493 900 
(2 321 600–2 636 400)
68 800 
(45 500–97 700)
2 562 600 
(2 380 200–2 711 800)
Low-middle SDI 
countries
91 700 
(81 600–102 000)
12·6 
(11·2–14·1)
48 300 
(42 900–54 000)
6·6 
(5·9–7·4)
3 821 300 
(3 385 500–4 278 800)
36 000 
(25 000–49 400)
3 857 300 
(3 412 700–4 320 000)
Low SDI countries 67 900 
(61 400–74 100)
10·5 
(9·5–11·5)
38 000 
(34 300–41 500)
5·9 
(5·3–6·4)
3 042 300 
(2 738 200–3 317 500)
26 000 
(18 100–34 400)
3 068 400 
(2 763 800–3 345 100)
Cancers
Global acute 
lymphoblastic 
leukaemia
59 100 
(50 000–66 700)
2·3 
(2·0–2·6)
18 700 
(16 600–21 100)
0·7 
(0·6–0·8)
1 479 400 
(1 308 800–1 665 100)
25 700 
(17 600–36 200)
1 505 100 
(1 331 700–1 701 100)
Global acute myeloid 
leukaemia
22 000 
(18 700–24 400)
0·9 
(0·7–1·0)
10 400 
(8800–11 700)
0·4 
(0·3–0·5)
827 100 
(699 800–921 900)
4900 
(3400–6600)
832 000 
(704 500–928 500)
Global leukaemias not 
otherwise specified*
68 400 
(56 900–77 800)
2·7 
(2·2–3·1)
19 700 
(16 700–22 100)
0·8 
(0·6–0·9)
1 565 900 
(1 323 600–1 750 800)
30 000 
(19 700–42 000)
1 595 900 
(1 347 800–1 780 800)
Global non-Hodgkin 
lymphomas
29 500 
(26 700–32 600)
1·1 
(1·0–1·3)
14 000 
(12 500–15 700)
0·5 
(0·5–0·6)
1 113 200 
(987 500–1 253 000)
12 100 
(8400–16 800)
1 125 300 
(997 000–1 267 300)
Global Hodgkin 
lymphomas
14 700 
(12 200–17 100)
0·6 
(0·5–0·6)
4500 
(3500–5400)
0·2 
(0·1–0·2)
343 600 
(268 400–417 100)
6900 
(4600–9500)
350 400 
(273 800–425 800)
Global brain and 
nervous system cancers
67 400 
(58 400–76 400)
2·6 
(2·3–3·0)
25 800 
(22 300–29 500)
1·0 
(0·9–1·1)
2 056 900 
(1 774 400–2 353 300)
31 300 
(21 400–43 500)
2 088 300 
(1 802 700–2 389 500)
Global liver cancers 3500 
(3200–3800)
0·1 
(0·1–0·1)
2600 
(2400–2800)
0·1 
(0·1–0·1)
197 000 
(181 000–213 900)
800 
(600–1000)
197 800 
(181 800–214 700)
Global renal cancers 24 400 
(21 900–26 800)
1·0 
(0·9–1·1)
3100 
(2800–3300)
0·1 
(0·1–0·1)
252 500 
(229 200–275 800)
10 500 
(6700–15 500)
262 900 
(237 800–287 500)
Global other rare 
cancers†
29 400 
(27 600–31 200)
1·1 
(1·0–1·1)
7200 
(6800–7600)
0·3 
(0·3–0·3)
514 000 
(485 400–540 800)
16 100 
(11 400–21 600)
530 100 
(500 500–558 700)
Global uncategorised 
cancers‡
98 300 
(89 200–106 400)
3·8 
(3·5–4·2)
36 200 
(32 600–39 700)
1·4 
(1·3–1·5)
2 886 900 
(2 590 600–3 171 600)
174 900 
(108 400–267 100)
3 061 800 
(2 752 800–3 367 000)
Absolute incidence, mortality, YLLs, YLDs, and DALYs represent the total childhood cancer (0–19 years, both sexes combined) values, rounded to the nearest hundred. Rates are reported per 100 000 person-years. 
SDI categories do not sum to precisely the global total because GBD does not provide separate estimates for all locations globally and an adjustment factor is made between all estimated locations, which each have 
a corresponding estimated SDI value for 2017, and the global aggregate. Causes refer to overall childhood cancer unless a specific cancer type is stated. DALYs=disability-adjusted life-years. SDI=Socio-demographic 
Index. UI=uncertainty interval. YLDs=years of life lived with disability. YLLs=years of life lost. *Included leukaemias not otherwise specified, chronic lymphocytic leukaemias, and chronic myeloid 
leukaemias.†Cancers with less than 1000 total deaths globally in 2017. ‡Cancers without a detailed GBD cause.
Table: Childhood cancer burden, 2017
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DALY estimates.13 More detailed descriptions of the 
methods for disease burden estimation can be found in 
the appendix for this paper and in the GBD 2017 capstone 
publications.13,17–19
Definitions
The childhood age group in this analysis encompasses 
children and adolescents, defined as ages 0–19 years. The 
0–14-year age range is used to define paediatrics in some 
countries and global health organisations, and data for 
subsets of this age range are available online using the 
GBD Compare Tool and the GBD Results Tool. All cancers 
as defined in the 10th revision of the International 
Classification of Diseases, chapter II (neoplasms), are 
included in the GBD cancer estimation process 
(appendix p 10). Only malignant neoplasms were included 
in this analysis; non-melanoma skin cancers were 
excluded. In this analysis, we restructured the cancer 
diagnostic categories to depict the most relevant childhood 
cancer information, categorising any cancer with less than 
1000 global deaths annually as other rare cancers, and any 
cancer without a specific GBD cause as uncategorised 
cancers. All rates in this paper are reported per 
100 000 person-years, with the GBD 2017 world standard 
population used for calculation of age-standardised rates.17 
See the appendix for definitions of GBD world super-
regions (p 54) and GBD world regions (p 60).
GBD 2017 produced estimates at global, regional, 
national, and select subnational levels; 13 this analysis 
focuses on the global and regional estimates. Country 
and subnational estimates are available online using the 
GBD Compare and GBD Results tools. Results are 
presented by Socio-demographic Index (SDI) quintile in 
a subset of tables and figures given the usefulness of 
SDI as a summary measure of where countries are on 
the development spectrum (appendix p 47). SDI is a 
composite measure of income per capita, total fertility 
rate under 25 years of age, and average educational 
attainment, and has been shown to correlate well with 
health outcomes.19
Uncertainty analysis
Final point estimates are reported with 95% uncertainty 
intervals (UIs). The UIs were calculated as the 2·5th and 
97·5th percentile of the distribution of 1000 draws at 
each step in the cancer estimation process, with the 
uncertainty propagated through each step (UI estimation 
is described in further detail in the appendix p 39).
Role of the funding source
The funders of this research had no role in the design of 
the GBD cancer estimation process, collection or 
analysis of data, interpretation of results, or in the 
writing of this manuscript. The corresponding author 
had full access to all data used in this study and had 
final responsibility for the decision to submit for 
publication.
Results
Childhood cancer resulted in 11·5 million (95% UI 
10·6–12·3) DALYs globally in 2017, of which 97·3% 
(97·3–97·3) came from YLLs and 2·7% (2·7–2·7) came 
from YLDs (table). A substantial portion of the global 
burden of childhood cancer exists in low, low-middle, 
and middle SDI countries (82·2% [82·1–82·2] of the 
global childhood cancer total DALYs; table), countries 
that are concentrated in Asia, Africa, and Central and 
South America (figure 1A). This geographical pattern of 
cancer burden distribution is noticeably different from 
that observed in adults (figure 1B), with only 50·3% 
(50·3–50·3) of the global adult cancer absolute DALY 
burden affecting low, low-middle, and middle SDI 
countries (appendix p 66).
Of the childhood cancer age groups, the 0–4-year age 
group had the greatest contribution to global childhood 
cancer DALYs (4·3 million [95% UI 3·8–4·7], or 37·0% 
[36·9–37·0] of the global 0–19 year childhood cancer 
absolute DALY burden; figure 2). Across all childhood 
cancer age groups, a consistently higher proportion of 
total DALYs was made up by YLLs (96·8% [96·8–96·8] 
to 98·1% [98·1–98·1] of the total age group-specific 
DALYs) than by YLDs (1·9% [1·9–1·9] to 3·2% [3·2–3·2] 
of the total age group-specific DALYs; appendix p 68). 
Leukaemias constituted the highest proportion of 
categorised childhood cancer DALY burden globally, 
followed by brain and nervous system cancers, with 
34·1% (34·0–34·1) of all childhood cancer DALYs 
globally attributable to leukaemias and 18·1% (18·1–18·1) 
attributable to brain and nervous system cancers. 
These two cancer types contributed to the greatest 
proportional categorised DALY burden globally in 
all childhood age groups, except for adolescents 
(15–19 years). In adolescents, other rare cancers, which 
include cancers such as those of the testes, ovaries, and 
thyroid, contributed the second highest proportional 
DALY burden categorised (19·5% [19·4–19·5]). There 
was a substantial proportion of uncategorised cancers, 
those neoplasms without a specific cancer type noted in 
the current GBD data structure, throughout the child-
hood and adolescent age range, representing 26·5% 
Figure 1: Global map of age-standardised DALY rates for (A) childhood 
cancers (ages 0–19 years) and (B) adult cancers (20 years or older), both 
sexes combined, 2017
Quintiles are based on DALYs per 100 000 person-years. For childhood cancers, 
quintile 1 indicates less than 222, quintile 2 indicates 222 to less than 263, 
quintile 3 indicates 263 to less than 346, quintile 4 indicates 346 to less than 
441, and quintile 5 indicates 441 or more. For adult cancers, quintile 1 indicates 
less than 3314, quintile 2 indicates 3314 to less than 3915, quintile 3 indicates 
3915 to less than 4407, quintile 4 indicates 4407 to less than 4964, and 
quintile 5 indicates 4964 or more. Adult cancer burden portrayed in this figure 
excluded non-melanoma skin cancers and benign tumours in order to be 
comparable to the childhood cancer burden map. ATG=Antigua and Barbuda. 
DALY=disability-adjusted life-year. FSM=Federated States of Micronesia. 
Isl=Islands. LCA=Saint Lucia. TLS=Timor-Leste. TTO=Trinidad and Tobago. 
VCT=Saint Vincent and the Grenadines.
For the GBD Compare Tool see 
https://vizhub.healthdata.org/
gbd-compare/
For the GBD Results Tool see 
http://ghdx.healthdata.org/gbd-
results-tool
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A
B
Persian GulfCaribbean LCA
Dominica
ATG
TTO
Grenada
VCT
TLS
Maldives
Barbados
Seychelles
Mauritius
Comoros
West Africa Eastern 
Mediterranean
Malta
Singapore Balkan Peninsula Tonga
Samoa
FSM
Fiji
Solomon Isl
Marshall Isl
Vanuatu
Kiribati
Persian GulfCaribbean LCA
Dominica
ATG
TTO
Grenada
VCT
TLS
Maldives
Barbados
Seychelles
Mauritius
Comoros
West Africa Eastern 
Mediterranean
Malta
Singapore Balkan Peninsula Tonga
Samoa
FSM
Fiji
Solomon Isl
Marshall Isl
Vanuatu
Kiribati
Quintile 1 (0–20%)
Quintile 2 (21–40%)
Quintile 3 (41–60%)
Quintile 4 (61–80%)
Quintile 5 (81–100%)
Age-standardised DALY rate 
quintiles for childhood cancers
Quintile 1 (0–20%)
Quintile 2 (21–40%)
Quintile 3 (41–60%)
Quintile 4 (61–80%)
Quintile 5 (81–100%)
Age-standardised DALY rate 
quintiles for adult cancers
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(26·5–26·5) of all childhood cancers globally. The 
proportion of uncategorised cancers was highest in the 
0–4-year age group (34·0% [33·9–34·0]), some of which 
might be attributable to cancers such as retinoblastoma 
and neuroblastoma, which are not currently separately 
estimated.
When assessed by GBD world region (figure 3), there 
was substantial variability in the absolute and pro-
portional DALY burden of childhood cancers by cancer 
type. Estimates of the proportion of childhood cancer 
DALYs comprised by leukaemias and brain and nervous 
system cancers, the most common childhood cancer 
types in many high-resource settings, both varied by up 
to 2·7 times between world regions. The greatest 
proportional burden of leukaemias was in Andean Latin 
America (49·4% [95% UI 49·1–49·7] of all childhood 
cancers) and central Latin America (48·7% [48·6–48·9] 
of all childhood cancers), whereas the greatest absolute 
burden rested in south Asia (954 000 [805 000–1 119 000] 
DALYs) and east Asia (695 000 [580 000–763 000] DALYs). 
Non-Hodgkin lymphomas, which include subtypes such 
as Burkitt’s lymphomas that are not separately estimated 
in the GBD study, varied by approximately three times 
between world regions, with the greatest proportional 
childhood cancer DALY burden in eastern sub-Saharan 
Africa (16·5% [16·5–16·6] of all childhood cancers) and 
western sub-Saharan Africa (16·1% [16·0–16·1] of all 
childhood cancers). The pro portion of childhood cancers 
that were uncategorised was prominent in all world 
regions, but disproportionately high in regions within 
sub-Saharan Africa (eg, 42·0% [41·9–42·1] in western 
sub-Saharan Africa).
Rankings of the relative burden of childhood cancers 
are shown in figure 4, expressed in absolute DALYs by 
SDI quintile, GBD super-region, and the 50 most 
populous countries for children in 2017. The intercategory 
rankings show that the low-middle SDI quintile had the 
greatest DALY burden for the majority of childhood 
cancer types, and the low SDI quintile had the most 
childhood cancer types that ranked second in DALY 
burden. Although four of the five countries with the 
highest childhood cancer DALYs were in the GBD super-
regions (1) south Asia and (2) southeast Asia, east Asia, 
and Oceania, sub-Saharan Africa had the greatest DALY 
burden for more childhood cancer types than any other 
super-region. The intra-category rankings highlight that 
for most countries, GBD super-regions, and SDI settings, 
uncategorised cancers had the highest estimated DALY 
burden of all the childhood cancer types.
Focusing on the representation of childhood cancer 
burden in terms of DALYs is not meant to devalue the 
importance of more standard cancer burden metrics. The 
absolute incidence and mortality values and age-
standardised rates for childhood cancers globally in 2017 
are presented in the table, and the relationship between 
country-level age-standardised childhood cancer incidence 
or mortality rates and SDI are shown in figure 5. With 
increasing SDI, age-standardised childhood cancer 
incidence rates generally increased, and age-standardised 
childhood cancer mortality rates decreased (figure 5).
Although the absolute incidence and mortality attri-
buted to childhood cancers numbered in the hundreds 
of thousands globally, the burden as represented 
by YLLs and DALYs was substantially greater, in the 
millions globally (table). Compared with cancers of 
adulthood (figure 6A), childhood cancers collectively 
ranked first in terms of DALY contribution in low and 
low-middle SDI countries, higher than the DALY burden 
attributable to any single adult cancer type. In higher SDI 
settings, the burden and ranking of individual adult 
cancers increased, and the ranking of childhood cancer 
DALYs congruently decreased. Globally, childhood cancer 
Figure 2: Global DALY burden of childhood cancer types, both sexes combined, 2017, in absolute and proportional burden in the 0–19 years age group (A), 
and absolute and proportional burden by 5-year childhood age group (B, C)
DALY=disability-adjusted life-year. *Cancers without a detailed GBD cause. †Cancers with less than 1000 total deaths globally in 2017. ‡Included leukaemias not 
otherwise specified, chronic lymphocytic leukaemias, and chronic myeloid leukaemias.
Childhood cancer type
Uncategorised cancers*
Other rare cancers†
Renal cancers
Liver cancers
Brain and nervous system cancers
Hodgkin lymphoma
Non-Hodgkin lymphoma
Leukaemias not otherwise 
specified‡
Acute myeloid leukaemia
Acute lymphoblastic leukaemia
0–19
0
3 000 000
6 000 000
9 000 000
12 000 000
A B C
0
25
50
75
100
DA
LY
s
Proportion of DALYs (%
)
Age group
(years)
0–4 5–9 10–14 15–19
0
1 125 000
2 250 000
3 375 000
4 500 000
DA
LY
s
Age group
(years)
0–4 5–9 10–14 15–19
0
25
50
75
100
 P
ro
po
rt
io
n 
of
 D
AL
Ys
 (%
)
Age group
(years)
Articles
www.thelancet.com/oncology   Vol 20   September 2019 1217
ranked sixth in terms of DALY burden, with a DALY 
burden lower only than the burden attributable to cancers 
of the lung, liver, stomach, colon, and breast. This 
ranking pattern was different when childhood cancers 
were compared with other diseases of childhood 
(figure 6B), in which the highest childhood cancer DALY 
burden ranking was in high-middle and middle SDI 
settings—countries that generally have transitioning 
development status—rather than the lowest SDI settings. 
Compared with other diseases of childhood, childhood 
cancer ranked ninth globally in terms of DALY burden, 
lower than the global burden of lower respiratory 
infections, diarrhoeal diseases, malaria, and HIV or 
AIDS, but higher than the global burden of measles, 
typhoid, and tuberculosis.
Discussion
To our knowledge, this paper is the first analysis to 
quantify the global burden of childhood cancer using 
DALYs. A standard global health metric routinely applied 
in health policy decision making, DALYs provide a 
more comprehensive, lifelong perspective to quantifying 
Figure 3: The absolute (A) and proportional (B) DALYs due to childhood (0–19 years) cancer types by GBD world region, both sexes combined, 2017
See the appendix for definitions of GBD world super-regions (p 54) and regions (p 60). DALY=disability-adjusted life-year. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. *Cancers 
without a detailed GBD cause. †Cancers with less than 1000 total deaths globally in 2017. ‡Included leukaemias not otherwise specified, chronic lymphocytic leukaemias, and chronic myeloid 
leukaemias.
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Figure 4: Childhood cancers 
ranked by number of DALYs 
for both sexes combined, 
2017
Inter-category ranking refers 
to ranking vertically (ranking 
between the SDI quintiles, 
between the GBD 
super-regions, and between 
countries). Intra-category 
ranking refers to ranking 
horizontally (ranking within 
each SDI quintile, within each 
GBD super-region, and within 
each country). Colour intensity 
is proportional to absolute 
DALYs within the category of 
ranking (within the column or 
row). Number ranking is 
assigned by total absolute 
DALYs, with 1 representing the 
highest rank and greatest 
absolute DALY burden. 
For definition of GBD world 
superregions see the appendix 
(p 54). The high-income GBD 
super-region includes the GBD 
regions of Australasia, 
high-income Asia Pacific, 
high-income North America, 
western Europe, and southern 
Latin America. SDI quintiles 
are ordered from high to low 
SDI quintile, and GBD super 
regions are alphabetically 
ordered. Country order 
selected by total absolute 
DALYs; countries with the 
greatest total absolute DALYs, 
of the fifty most populous 
countries in the world, are 
listed first. The most populous 
countries are defined by total 
childhood (ages 0–19 years) 
population. DALY=disability-
adjusted life-year. GBD=Global 
Burden of Diseases, Injuries, 
and Risk Factors Study. 
SDI=Sociodemographic Index. 
*Included leukaemias not 
otherwise specified, chronic 
lymphocytic leukaemias, 
and chronic myeloid 
leukaemias. †Cancers with less 
than 1000 total deaths 
globally in 2017. ‡Cancers 
without a detailed GBD cause.
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childhood cancer burden than has been reported in the 
past. Previous approaches to reporting the global burden 
of childhood cancers have focused on incidence, 
mortality, and survival; each of these metrics, although 
essential, provide a limited assessment when reviewed 
individually.6,7,12 DALYs can provide a useful summary 
measure of early mortality and treatment-related 
morbidity, especially for the childhood cancer population, 
in which early deaths contribute many YLLs to DALYs 
and in which children surviving cancer treatment often 
live for many years with chronic disability. In our analysis 
of GBD 2017, we report that although the absolute 
numbers of global childhood cancer incident cases 
and deaths were relatively small, the global burden 
of childhood cancer as represented in DALYs was 
substantial. The majority of these childhood cancer 
DALYs affected countries with a lower SDI, probably due 
to both the younger population structure observed in 
lower-income settings as well as a disproportionately 
large YLL burden, reflective of the lower survival rates 
observed in countries with frail health systems.
As expected, lower SDI settings were noted to have 
the highest age-standardised overall childhood cancer 
mortality rates. However, the association between 
childhood cancer incidence rates and SDI represented 
in figure 5A is unexpected, given that there are few 
established environmental risk factors for the majority of 
childhood cancers and current evidence suggests that 
pathological germline cancer predisposition mutations 
affect less than 10% of the childhood cancer population.8,20 
The cause of the trend between incidence and SDI is 
unknown but probably multifactorial. Although there is 
heterogeneity in environmental exposures between world 
regions and much to learn regarding potential genetic 
variability between populations, these factors alone are 
unlikely to explain the estimated variation in childhood 
cancer incidence by SDI. Limitations in access to health 
care and diagnostic capacity for children with cancer have 
been suggested to contribute to artificially low case 
ascertainment in resource-limited settings.21 Missed 
diagnoses caused by poor access to health facilities, 
misdiagnoses as non-oncological diseases, and under-
registration due to overburdened cancer registration 
systems all probably contribute to this phenomenon. The 
GBD 2017 results highlight that improving the accuracy of 
global childhood cancer burden assessment will require 
not only expanding the quantity and quality of population-
based cancer registration systems, but also increasing 
access to health care with the capacity to identify children 
with cancer regardless of where they live.
Treatment of childhood cancer in LMIC settings has 
been shown to be very cost-effective according to WHO–
Choosing Interventions that are Cost-Effective criteria, 
but because of finite resources and competing health 
priorities in many LMIC settings, an accurate appraisal 
of childhood cancer disease burden using comparable 
metrics is essential for health policy decision making.22,23 
As low SDI countries develop, the burden of infectious 
diseases tends to decline and thus the relative burden 
of non-communicable diseases, including cancers, tends 
to rise—a phenomenon known as epidemiological tran-
sition. The use of DALYs provides a unique ability to 
contextualise the burden of childhood cancers in 
comparison with general diseases of childhood, and we 
found that childhood cancer ranks among the top 
five causes of DALY burden in middle and high-middle 
SDI settings, with a lower ranking on either end of the 
SDI spectrum, particularly in low SDI settings. This 
pattern is consistent with the epidemiological transition, 
with the highest childhood cancer burden relative to the 
burden of general diseases of childhood occurring in 
countries transitioning from lower to higher develop-
ment status.
A different DALY pattern was observed when childhood 
cancers were compared with individual adult cancers— 
a suitable comparison for guidance of resource allo cation 
Figure 5: The association between SDI and childhood cancer age-standardised incidence rate (A) and 
mortality rate (B), 2017
Both panels represent estimates for both sexes combined. Each colour represents one of the seven GBD super-regions 
(red represents southeast Asia, east Asia, and Oceania; blue represents central Europe, eastern Europe, and central 
Asia; green represents high-income; purple represents Latin America and the Caribbean; orange represents 
North Africa and the Middle East; yellow represents south Asia; and grey represents sub-Saharan Africa). GBD region 
point estimates are median overall childhood cancer incidence or mortality rates due to inter-region variability. 
Lighter-coloured point estimates without labels in the legend represent countries. Country estimates are mean 
overall childhood cancer incidence or mortality rates. The black lines represent locally weighted smoothing based on 
country-level data, and the grey lines represent locally weighted smoothing of country-level 95% uncertainty 
intervals. See the appendix for definitions of GBD world super-regions (p 54) and regions (p 60). GBD=Global Burden 
of Diseases, Injuries, and Risk Factors Study. SDI=Socio-demographic Index.
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decisions given that childhood cancers are typically 
treated under one clinical service, whereas adult cancers 
are often treated under various cancer-specialised 
services. Specifically, childhood cancers are the top cause 
of cancer burden, as expressed in DALYs, in low and 
low-middle SDI settings. This is a markedly different 
concentration of burden than occurs in adult cancers, in 
which DALY burden is heavily weighted towards countries 
Figure 6: Contribution of childhood cancer to global cancer (A) and child health (B) DALY burden, both sexes combined, 2017
Disease rank assigned by total absolute DALYs globally in 2017. Childhood cancer burden is represented by the total DALYs for population aged 0–19 years. Adult 
cancer burden is represented by the total DALYs for each cancer subtype for the population aged 20 years and older. Total DALYs are rounded to the nearest hundred. 
Colour intensity is proportional to rank number. (A) All cancer causes are included. (B) Top 20 global causes of absolute DALY burden in children aged 0–19 years; 
childhood diseases excluded injuries and perinatal diseases. DALY=disability-adjusted life-year. SDI=Socio-demographic Index. UI=uncertainty interval.
Total DALYs (95% UIs) in 2017 Global
rank
High
SDI rank
High-middle 
SDI rank
Middle SDI 
rank
Low-middle 
SDI rank
Low
SDI rank
Tracheal, bronchus, and lung cancer 40 876 700 (39 966 500–41 802 900)
Liver cancer 20 567 900 (19 725 300–21 580 700)
Stomach cancer 19 086 900 (18 694 500–19 524 200)
Colon and rectum cancer 18 931 700 (18 447 000–19 429 000)
Breast cancer 17 678 800 (16 872 800–18 645 200)
Oesophageal cancer 9 762 300 (9 517 700–10 015 700)
Pancreatic cancer 9 069 100 (8 883 200–9 245 300)
Other malignant neoplasms 8 805 300 (8 154 100–9 137 700)
Cervical cancer 8 046 300 (7 513 100–8 385 100)
Prostate cancer 7 052 600 (6 048 700–8 347 200)
Brain and nervous system cancer 6 656 500 (5 827 800–7 170 100)
Non-Hodgkin lymphoma 5 896 600 (5 759 100–6 028 400)
Lip and oral cavity cancer 5 204 800 (4 933 700–5 447 800)
Ovarian cancer 4 630 300 (4 488 000–4 786 900)
Bladder cancer 3 590 300 (3 468 600–3 759 800)
Gallbladder and biliary tract cancer 3 476 400 (3 036 000–3 706 400)
Larynx cancer 3 270 500 (3 183 300–3 365 900)
Other pharynx cancer 3 243 700 (2 804 300–3 444 700)
Other leukaemia 3 121 400 (2 713 700–3 367 800)
Kidney cancer 3 021 400 (2 838 400–3 122 600)
Acute myeloid leukaemia 2 389 400 (2 182 900–2 528 600)
Multiple myeloma 2 311 400 (2 163 200–2 594 200)
Uterine cancer 2 136 800 (2 052 500–2 221 800)
Nasopharynx cancer 2 021 900 (1 942 300–2 105 600)
Malignant skin melanoma 1 637 100 (1 319 200–1 917 800)
Acute lymphoid leukaemia 1 199 600 (1 044 400–1 282 800)
Thyroid cancer 1 092 200 (1 034 200–1 181 500)
Hodgkin lymphoma 1 027 700 (883 500–1 209 300)
Chronic lymphoid leukaemia 698 600 (658 200–743 100)
Mesothelioma 665 100 (643 100–686 700)
Chronic myeloid leukaemia 633 200 (574 900–688 500)
Testicular cancer 351 300 (333 400–373 500)
Lower respiratory infections 75 181 700 (69 730 900–80 925 200)
Diarrhoeal diseases 55 376 300 (49 770 900–61 257 900)
Congenital birth defects 51 381 000 (48 552 300–54 613 300)
Malaria 37 019 400 (25 399 000–51 171 500)
Meningitis 16 155 400 (13 770 000–18 572 700)
Dietary iron deficiency 14 762 900 (9 852 600–21 167 000)
Protein-energy malnutrition 14 347 400 (12 739 100–16 048 300)
HIV or AIDS 13 111 300 (12 143 600–14 126 00)
Childhood cancer 11 549 600 (10 649 900–12 334 700)
Sexually transmitted infections excluding HIV 9 921 800 (3  915 600–18 770 800)
Headache disorders 8 247 400 (5 352 800–11 832 100)
Vitamin A deficiency 8 197 400 (5 334 100–12 002 700)
Measles 8 105 900 (2 934 000–17 455 900)
Whooping cough 7 935 600 (3 994 100–14 019 900)
Typhoid and paratyphoid 7 710 700 (4 429 600–12 589 100)
Tuberculosis 7 561 500 (6 917 000–8 235 200)
Conduct disorder 6 101 100 (3 653 500–9 815 600)
Dermatitis 5 858 300 (3 215 100–9 674 000)
Epilepsy 5 766 300 (4 355 600–7 485 200)
Anxiety disorders 5 714 600 (3 957 000–7 911 800)
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Childhood cancer 11 549 600 (10 649 900–12 334 700)
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with high and middle SDI status, and is probably due in 
part to the older population structure in higher SDI 
settings, as well as to lifestyle risk factors that are more 
prevalent in higher-resourced settings.24 This variation in 
the epidemiological patterns of cancer burden distribution 
in children and adults supports the view that the 
mechanisms of addressing cancer burden in adults, 
which focus on risk-reduction strategies and screening 
interventions, are not as relevant in the paediatric and 
adolescent age groups at this time. Childhood cancers 
generally progress rapidly, are not amenable to screening, 
and are fatal without swift diagnosis and treatment.8 
Thus, improving childhood cancer outcomes will require 
well functioning health systems capable of early diagnosis 
and effective treatment.
Addressing the global burden of childhood cancer has 
gained greater relevance during the past 2 years since 
the World Health Assembly Cancer Resolution in May, 
2017, and the WHO Global Initiative for Childhood 
Cancer announced during the High Level Meeting on 
non-communicable diseases at the UN General 
Assembly in September, 2018.25,26 The World Health 
Assembly Cancer Resolution requested resource-
stratified guidance for the development of cancer-control 
programmes, specifically calling for children and 
adolescents to be included in the design of these 
programmes. The WHO Global Initiative for Childhood 
Cancer is the first programme designed to address this 
resolution with a focus on childhood cancer and aims to 
increase the overall survival for six key childhood cancers 
(acute lymphoblastic leukaemia, Burkitt’s lymphoma, 
Hodgkin lymphoma, low-grade glioma, retinoblastoma, 
and Wilms tumour) to 60% globally by 2030 through 
integration of childhood cancer into national cancer 
control policies and capacity-building interventions 
including the development of national centres of 
excellence and regional satellites.5 As initiatives such as 
these recommend countries develop and implement 
paediatric-specific cancer control plans over the next 
decade, country-specific and region-specific variations in 
disease burden and identification of high-yield 
opportunities for improvement in outcomes will be 
essential. In particular, evaluating the progress made in 
childhood cancer survival as part of the WHO Global 
Initiative for Childhood Cancer will be imperative to its 
success. The GBD study provides valuable estimates of 
childhood cancer epidemiology in areas where direct 
disease burden data are scarce or non-existent, provides 
the most comprehensive and contextualised global 
burden estimates to date through the use of DALYs, and 
is updated annually. Moreover, the GBD framework is 
already monitoring progress of the health-related UN 
Sustainable Development Goals.27,28 As the WHO Global 
Initiative for Childhood Cancer will develop indicators 
similar in structure to those used for tracking of 
Sustainable Development Goal targets, the GBD study 
provides an ideal platform for monitoring global 
progress in childhood cancer by quantifying changes in 
burden and tracking proposed indicators over time.
The deeper analyses of the GBD cancer estimation 
process described here highlight opportunities to 
improve the currently applied methodology with regard 
to childhood cancers in particular. Inclusion of data from 
paediatric-specific cancer registries would add key 
existing information for childhood cancer incidence not 
currently included in the GBD data sources.7 However, 
additional data sources alone will not resolve key 
structural limitations in the existing GBD approach. The 
present anatomical site-based system of reporting cancer 
types functions well for adult cancers, which are 
primarily carcinomas, but leaves 26·5% of childhood 
cancer DALYs globally with a label of uncategorised 
cancers. Morphology is crucial to appropriate diagnosis 
and treatment of childhood cancers, and thus the current 
GBD classification system inadequately communicates 
the burden of childhood cancers and represents a missed 
opportunity for actionable burden estimates. Using the 
International Classification of Childhood Cancer system 
as a framework for reporting childhood cancers would 
decrease the notable proportion that are uncategorised 
and should be prioritised in future GBD iterations.29 
A separate limitation in the reporting is that although 
GBD 2017 provided estimates for benign tumour burden 
in aggregate, it did not specify the portion attributable to 
CNS tumours. Thus, the estimates reported here do not 
include these tumours, which are important contributors 
to childhood cancer morbidity and include one of the 
six indicator cancers (low-grade gliomas) proposed by the 
WHO Global Initiative for Childhood Cancer.25
Furthermore, the current GBD approach to modelling 
the treatment and survivorship phases of childhood 
cancer care might lead to a systematic underestimation 
of YLDs and DALYs. First, the estimation of YLDs relies 
on data for prevalence sequelae duration from HICs. 
However, superimposing HIC data in this manner might 
not accurately represent the duration of disability seen in 
LMICs. This consideration is important because children 
in LMIC settings tend to present to care later in their 
disease course, potentially leading to different distri-
butions of cancer stage at diagnosis than are observed 
in HICs.3 Addressing this issue was not historically 
possible because of a paucity of childhood cancer staging 
information in population-based cancer registries.30 
If the recently published Toronto guidelines providing 
concrete staging recom mendations are adopted by 
registries in the coming years, however, opportunities to 
use staging data to improve the estimation of YLDs 
might be possible in the near future.30 Second, the 
current GBD estimation of YLDs assumes that all 
children receive and complete treatment. Unfortunately, 
many children with cancer in LMIC settings have notable 
risk of therapy abandon ment.31 Although global data on 
childhood cancer abandonment are limited, creating a 
method to account for the proportion of children who 
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abandon therapy upfront is imperative given that 
untreated childhood cancer is generally fatal. Finally, the 
current GBD models do not incorporate the well 
established increased lifelong risk of multimorbidity and 
early death observed in childhood cancer survivors 
compared with the general population.32–34 The existing 
modelling of disability in childhood cancer survivors is 
limited to 10 years after cancer diagnosis, with children 
surviving past 10 years presumed to have the same risk of 
morbidity and mortality as the general population. 
Substantial data have shown this assumption to be 
inaccurate, and incorporation of survivorship cohort data 
would improve the GBD estimation of childhood cancer 
survivor burden.33,34
These limitations suggest that the GBD 2017 estimates 
probably underestimate the DALYs associated with 
childhood cancer. Addressing these limitations in future 
GBD iterations would improve childhood cancer burden 
estimates and provide a better evidence base for policy, 
financial, and clinical decision making. Opportunities to 
improve on the current GBD methodology are both 
feasible and necessary to provide the most useful 
information to global health stakeholders interested in 
reducing disparities in global childhood cancer outcomes.
In summary, this analysis of the global burden of 
childhood cancer produced by the GBD 2017 study 
demonstrates substantial DALY burden, even when 
compared with cancers in adults and general diseases of 
childhood. Childhood cancer DALYs disproportionately 
affect countries with the fewest resources, underscoring 
the need for effective strategies to address the burden in 
these settings. These findings provide a global childhood 
cancer burden baseline from which to evaluate future 
progress and highlight that childhood cancer has a role 
in prioritisation frameworks that address global oncology 
and global child health.
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